tetano
Editor, Senior Moderator
PLoS One
. 2024 May 20;19(5):e0297272.
doi: 10.1371/journal.pone.0297272. eCollection 2024. Characterization of antibody response to SARS-CoV-2 Orf8 from three waves of COVID-19 outbreak in Thailand
Jeeraphong Thanongsaksrikul[SUP] 1 2 3 [/SUP], Paskorn Sritipsukho[SUP] 4 5 [/SUP], Potjanee Srimanote[SUP] 1 2 3 [/SUP], Onruedee Khantisitthiporn[SUP] 2 6 [/SUP], Wipawadee Sianglum[SUP] 7 [/SUP], Uayporn Pinitchai[SUP] 8 [/SUP], Yong Poovorawan[SUP] 9 [/SUP]
Affiliations
A dynamic of virus adaptation and a mass vaccination campaign could significantly reduce the severity of clinical manifestations of COVID-19 and transmission. Hence, COVID-19 may become an endemic disease globally. Moreover, mass infection as the COVID-19 pandemic progressed affected the serology of the patients as a result of virus mutation and vaccination. Therefore, a need exists to acquire accurate serological testing to monitor the emergence of new outbreaks of COVID-19 to promptly prevent and control the disease spreading. In this study, the anti-Orf8 antibodies among samples collected in Thailand's first, fourth, and fifth waves of COVID-19 outbreaks compared with pre-epidemic sera were determined by indirect ELISA. The diagnostic sensitivity and specificity of the anti-Orf8 IgG ELISA for COVID-19 samples from the first, fourth, and fifth waves of outbreaks was found to be 100% compared with pre-epidemic sera. However, the diagnostic sensitivity and specificity of the anti-Orf8 IgG ELISA for a larger number of patient samples and controls from the fifth wave of outbreaks which were collected on day 7 and 14 after an RT-PCR positive result were 58.79 and 58.44% and 89.19 and 58.44%, respectively. Our data indicated that some of the controls might have antibodies from natural past infections. Our study highlighted the potential utility of anti-Orf8 IgG antibody testing for seroprevalence surveys but still warrants further investigations.
. 2024 May 20;19(5):e0297272.
doi: 10.1371/journal.pone.0297272. eCollection 2024. Characterization of antibody response to SARS-CoV-2 Orf8 from three waves of COVID-19 outbreak in Thailand
Jeeraphong Thanongsaksrikul[SUP] 1 2 3 [/SUP], Paskorn Sritipsukho[SUP] 4 5 [/SUP], Potjanee Srimanote[SUP] 1 2 3 [/SUP], Onruedee Khantisitthiporn[SUP] 2 6 [/SUP], Wipawadee Sianglum[SUP] 7 [/SUP], Uayporn Pinitchai[SUP] 8 [/SUP], Yong Poovorawan[SUP] 9 [/SUP]
Affiliations
- PMID: 38768163
- DOI: 10.1371/journal.pone.0297272
A dynamic of virus adaptation and a mass vaccination campaign could significantly reduce the severity of clinical manifestations of COVID-19 and transmission. Hence, COVID-19 may become an endemic disease globally. Moreover, mass infection as the COVID-19 pandemic progressed affected the serology of the patients as a result of virus mutation and vaccination. Therefore, a need exists to acquire accurate serological testing to monitor the emergence of new outbreaks of COVID-19 to promptly prevent and control the disease spreading. In this study, the anti-Orf8 antibodies among samples collected in Thailand's first, fourth, and fifth waves of COVID-19 outbreaks compared with pre-epidemic sera were determined by indirect ELISA. The diagnostic sensitivity and specificity of the anti-Orf8 IgG ELISA for COVID-19 samples from the first, fourth, and fifth waves of outbreaks was found to be 100% compared with pre-epidemic sera. However, the diagnostic sensitivity and specificity of the anti-Orf8 IgG ELISA for a larger number of patient samples and controls from the fifth wave of outbreaks which were collected on day 7 and 14 after an RT-PCR positive result were 58.79 and 58.44% and 89.19 and 58.44%, respectively. Our data indicated that some of the controls might have antibodies from natural past infections. Our study highlighted the potential utility of anti-Orf8 IgG antibody testing for seroprevalence surveys but still warrants further investigations.